First time I've heard of filanesib (kinesin spindle inhibitor), and first time I've heard of a #MMsm drug specifically targeting gain(1q) 🎉🤯 (⚠️: One ?iatrogenic death from SJS) Congrats to @kaufman_MMdoc Ajai Chari and co-authors on this Ph1 study! onlinelibrary.wiley.com/doi/full/10.10…

1/ Huge thanks to Mike Thompson, MD, PhD, FASCO for keeping track of myeloma abstracts each year! My top 10 #ASCO24 #MMsm abstracts: Abstract #7501 (Leleu et al): IFM 2020-05. Isa-VRd (1x wkly Velcade 👏) beat Isa-Rd in ASCT-ineligible MM. Quads for all? (See next tweet) meetings.asco.org/abstracts-pres…

#mmsm #ASCO24 MajesTEC-1 - teclistamab ➡️ meetings.asco.org/abstracts-pres… ✅Median follow up:2.5 years ✅Median DOR: 2 years ✅Median PFS: ~ 1 year ✅Median OS: ~ 2 years 🛑>half pts with G3/4 infections, 13% (22/165) deaths related to infection (most 2ry to COVID)

Newly open application for the Advanced Fellowship in Leukemia Dana-Farber. Led by Marlise R. Luskin MD, MSCE Please share.

Out now in Journal of Hematology and Oncology: Impact of Extramedullary Multiple Myeloma on Outcomes with Ide-cel: jhoonline.biomedcentral.com/articles/10.11… Shaji Kumar Yi Lin Krina Patel Surbhi Sidana, MD #dorishansen Moffitt Cancer Center BMC Top line results and a brief 🧵 1/

Our work with Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 and David Chung at Memorial Sloan Kettering Cancer Center looking at antigen escape with BCMA-targeting therapies in #MMSM patients is now out in @BloodJournal authors.elsevier.com/a/1jUXn1UYwnDBZ 1/7

Extramedullary plasmacytoma in transplanted kidney: PTLD or MGRS? @BWHKidney Dana-Farber Journal of Onconephrology American Society of Onconephrology Bianchi Lab bit.ly/3AgfRFA

Many patients on BsAb therapy in #MultipleMyeloma discontinue Rx due to a severe toxicity (e.g. infection). But how long does remission hold once Rx stops? Could this hint whether fixed-duration BsAb therapy might offer lasting, treatment-free remission? Our multi-center study to

1/ Now in Blood Cancer Journal - our work to chronicle disparities specifically in R/R myeloma and why they matter 🧵 1️⃣ Trial-studied vs optimal drug dosing 2️⃣ Racial & socioeconomic gaps re: CAR-T & bsAbs 3️⃣ #MMsm supportive care, inc PCP access, and more nature.com/articles/s4140…

Hot off the press! Our #MultipleMyeloma Task Force position statement is now published in Blood Cancer Journal. Read the panelists' consensus statement on addressing disparities in #RRMM! nature.com/articles/s4140… Rahul Banerjee, MD, FACP Beth Faiman PhD Yelak Biru Craig Emmitt Cole Shonali Midha, M.D.

#Myeloma Paper of the Day: Optical genome mapping in conjunction w/ FISH, karyotyping & NGS detects MYC rearrangements in 43.3% of patients, and MYC protein over-expression in 72.7% of these cases, especially w/ translocations involving Ig loci: pubmed.ncbi.nlm.nih.gov/39304649/. #mmsm

#Myeloma Paper of the Day: Pre-clinical in vitro data suggest CD38/CD3xCD28 trispecific T-cell engager (SAR442257) may work in patients after prior daratumumab: pubmed.ncbi.nlm.nih.gov/39308023/. Interestingly, TCE lacking CD38-binding also worked, suggesting CD28 binding is enough. #mmsm

New: cilta-cel, a #CART for multiple myeloma, found highly effective in first real-world study. Read more from Surbhi Sidana, MD and colleagues today in @BloodJournal: ow.ly/PQrC50TEzlh #mmsm #Cartitude

Congrats Surbhi Sidana, MD and whole #MMsm Consortium on newest Blood Journal paper! RW cilta-cel CAR-T outcomes (n >200). Largely CART-1 ineligible, but pts overall did well. Among BCMA-exposed, ≥6 month washout reasonable pending better diagnostics. ashpublications.org/blood/article/…

Four institutions join together to form Cancer AI Alliance Fred Hutch Cancer Center Johns Hopkins University Dana-Farber Memorial Sloan Kettering Cancer Center techcrunch.com/2024/10/02/can…

Rahul Banerjee, MD, FACP Surbhi Sidana, MD Blood Journal Krina Patel Radhika Bansal Rakshit (She/Her) Shonali Midha, M.D. Binod Dhakal Danai Dima Ciara Freeman Yi Lin Murali Janakiram Jack Khouri Tom Martin Fascinating data. The major question is now long-term toxicities that we must continue to monitor. If MNT can be kept low, will be a major step forward. Will be interesting to see SPMs when used in earlier lines Critical publication. My mind map below: #mmsm

#Myeloma Paper of the Day: Single-cell analysis of myeloma TME after gamma-secretase inhibition & CAR T therapy finds reduction in non-classical monocytes & monoallelic BCMA deletion in some pts w/ prior anti-BCMA which correlated w/ reduced PFS: pubmed.ncbi.nlm.nih.gov/39374522/. #mmsm

Myeloma / Plasma Cell Dyscrasia ~ #ASH24Top10 (or so) #mmsm #mmMRD #ASH24 - Mike Thompson, MD, PhD, FASCO *DRAFT* Table Update: Nov 25, 2024 - cc Surviving Myeloma - Ben Derman Samer Al Hadidi, MD,MS,FACP Joseph Mikhael @MyelomaTeacher - Cindy Chmielewski Rahul Banerjee, MD, FACP Saad Z. Usmani MD MBA FACP 🇺🇸🇵🇰 et al.

Thanks VuMedi for featuring our Blood Advances piece around driving restrictions following CAR-T therapy in MM. Driving cars after CARs: an easy Twitter pun but a fundamentally important issue for pts. Data don't support 8-week driving restrictions! vumedi.com/video/driving-…